论文部分内容阅读
目的:评估康莱特(KLT)配伍吉非替尼治疗对晚期非小细胞肺癌(NSCLC)的免疫功能和生活质量的影响。方法:选取我院2013年1月-2014年7月诊治的晚期NSCLC患者64例并随机分为两组各32例。对照组给予吉非替尼口服,试验组在对照组基础上加KLT静脉滴注。观察两组T淋巴细胞亚群CD3~+、CD4~+、CD8~+、CD4~+/CD8~+表达情况及自然杀伤(NK)细胞活性;采用生活质量量表(QLQ-CCC)和卡式功能状态量表(KPS)对生活质量及功能状态进行评估。结果:试验组T淋巴细胞亚群CD4~+、CD4~+/CD8~+表达率及NK细胞活性高于对照组(P<0.05),且其治疗前后的差值低于对照组(P<0.05);试验组躯体、心理、社会、QLQ-CCC总分及KPS得分均高于对照组,且其治疗前后的差值均高于对照组(P<0.05)。结论:KLT配伍吉非替尼治疗晚期NSCLC可减少吉非替尼对免疫功能的损害,提高患者的生活质量。
Objective: To evaluate the effect of KLT combined with gefitinib on immune function and quality of life in advanced non-small cell lung cancer (NSCLC). Methods: Sixty-four patients with advanced NSCLC diagnosed and treated from January 2013 to July 2014 in our hospital were randomly divided into two groups of 32 cases. The control group was given gefitinib orally, and the experimental group was given KLT intravenously on the basis of the control group. The expression of CD3 ~ +, CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ + of T lymphocyte subsets and natural killer (NK) cell activity in the two groups were observed. The quality of life (QLQ-CCC) Functional status scale (KPS) to assess the quality of life and functional status. Results: The expression of CD4 ~ +, CD4 ~ + / CD8 + and T cell subsets in the experimental group were higher than those in the control group (P <0.05), and the differences between before and after treatment were lower than those in the control group (P < 0.05). The scores of somatic, psychological, social, QLQ-CCC and KPS in the experimental group were higher than those in the control group, and the differences between before and after treatment were higher than those in the control group (P <0.05). Conclusions: KLT combined with gefitinib in the treatment of advanced non-small cell lung cancer can reduce the damage to immune function of gefitinib and improve the quality of life of patients.